EUPRAXIA PHARMACEUTICALS INC. Research and Development Expense
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Research and Development Expense of $21.33 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-13
| Period end | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $21.33M 40-F · filed 2026-03-13 | |
| 2024-12-31 | $16.08M 40-F · filed 2026-03-13 | |
| 2023-12-31 | $20.36M 40-F · filed 2025-03-20 | $20.56M 40-F · filed 2024-04-01 |
| 2022-12-31 | $13.63M 40-F · filed 2024-04-01 |